A study for people looking to transition from Buprenorphine maintenance to VIVITROL
Up to 9 weeks, including Screening (up to 3 weeks), up to 2 weeks for Lead-in Period and residential Treatment Period receiving decreasing doses of Buprenorphine and increasing doses of either active or placebo Naltrexone, 4-5 days for VIVITROL induction and post-VIVITROL monitoring, and a 4-week outpatient follow-up period.
- Study Identifier: 825716
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required